ASH1L and hepatocellular carcinoma: The addition of recombinant CCL2 and CSF1 (rCCL2+rCSF1) supplements also reversed the HCC cell proliferation inhibition and CD8+ T cell activation phenotypes caused by ASH1L knockdown (Figure 5I,J; Figure S7A,B, Supporting Information).